Research Topics
Species | Suzanne L TopalianSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
Curr Opin Immunol 24:207-12. 2012..Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy...- Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
N Engl J Med 366:2443-54. 2012..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1... - Cancer immunotherapy comes of ageSuzanne L Topalian
Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 29:4828-36. 2011..Unlike conventional cancer therapies, most immunotherapies are active and dynamic, capable of inducing immune memory to propagate a successful rebalancing of the equilibrium between tumor and host... 
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer
Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 28:3167-75. 2010..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...- Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyEvan J Lipson
Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
Clin Cancer Res 19:462-8. 2013..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective... - Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer
Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
N Engl J Med 366:2455-65. 2012..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models... - Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeJanis M Taube
Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Sci Transl Med 4:127ra37. 2012..These observations suggest that therapies that block this pathway may benefit patients with B7-H1(+) tumors... - Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaSofia Lyford-Pike
Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Cancer Res 73:1733-41. 2013.... - Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapyFlorence R Depontieu
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Proc Natl Acad Sci U S A 106:12073-8. 2009..This previously undescribed demonstration of MHC II-restricted phosphopeptides recognizable by human CD4(+) T cells provides potential new targets for cancer immunotherapy...